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Abstract: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coron-
avirus 2 (SARS-CoV-2), has resulted in a global pandemic associated with substantial morbidity and
mortality worldwide, with particular risk for severe disease and mortality in the elderly population.
SARS-CoV-2 infection is driven by a pathological hyperinflammatory response which results in a
dysregulated immune response. Current advancements in aging research indicates that aging path-
ways have fundamental roles in dictating healthspan in addition to lifespan. Our review discusses
the aging immune system and highlights that senescence and aging together, play a central role
in COVID-19 pathogenesis. In our review, we primarily focus on the immune system response to
SARS-CoV-2 infection, the interconnection between severe COVID-19, immunosenescence, aging,
vaccination, and the emerging problem of Long-COVID. We hope to highlight the importance of
identifying specific senescent endotypes (or “sendotypes”), which can used as determinants of
COVID-19 severity and mortality. Indeed, identified sendotypes could be therapeutically exploited
for therapeutic intervention. We highlight that senolytics, which eliminate senescent cells, can target
aging-associated pathways and therefore are proving attractive as potential therapeutic options to
alleviate symptoms, prevent severe infection, and reduce mortality burden in COVID-19 and thus
ultimately enhance healthspan.
Keywords: senescence; aging; COVID-19; SARS-CoV-2; immunosenescence; sendotypes; severity;
mortality; vaccination; senolytics
1. Introduction
In the 1960s, Leonard Hayflick, reported the limited proliferative capacity of cultured
human diploid cells, where cells ceased to proliferate after serial passage in vitro. This
was the first introduction of the permanent state of cell cycle arrest which is referred to
as “cellular senescence” [1,2]. Hayflick is now respected as one of the most prominent
biologists in history, although his work and research discoveries were controversial at the
time as they contested Alexis Carrel’s earlier theory that cells are immortal [3]. Hayflick
completely abolished this dogma which was believed for 60 years and as such give rise to
a phenomenon known as the “Hayflick Limit”. The naming of this concept as the Hayflick
Limit was designated in 1974 by Frank Macfarlane Burnet after Leonard Hayflick [4], and is
a concept used worldwide to help explain and understand the mechanisms behind cellular
aging. This concept states that human cell populations will only replicate and divide
for a limited number of times before cell division completely stops and cells then enter
programmed cell death or apoptosis [2]. The concept of the Hayflick Limit underpinned
pioneering work by Elizabeth Blackburn, Jack Szostak and Carol Greider, who identified
and discovered the impacts and effects of shortening of repetitive DNA sequences, termed
telomeres, on the chromosome ends. This work facilitated scientists’ study to investigate
cellular aging from embryonic development to death [5,6]. Elizabeth Blackburn, Jack
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Szostak and Carol Greider received the Nobel Prize in Physiology or Medicine in 2009 for
their findings on telomeres and the enzyme telomerase both of which are associated with
the Hayflick Limit [7]. The observation of this type of cellular senescence, first introduced
by Hayflick, is also referred to as “replicative senescence” and is confirmed to be linked
with progressive telomere shortening every time the cell divides [8–11].
Senescence is a very exciting, fast-moving field of research. Life expectancy worldwide
is increasing, in parallel with this comes the significantly increased burden of public health
and economic challenges due to increased incidence of multiple chronic diseases and
disorders within the aging population, despite advances in science and medicine. Aging
and the connection with senescence is acknowledged as one of the core risk factors for many
of these chronic and life-threatening conditions such as cancer and cardiovascular disease.
This is possibly true also for coronavirus disease 2019 (COVID-19) where it is apparent that
the older population are at increased susceptibility to infection and more severe infection.
Therefore, many scientists across the world are frantically racing to investigate the field
thoroughly to prevent healthcare systems becoming overwhelmed.
Aging in all tissues is linked with elevated levels of cellular senescence, which is
triggered by various compounding extrinsic and intrinsic factors. This stress-induced
response process means cells permanently stop dividing and exit from the cell cycle and
acquire a pro-inflammatory senescence-associated secretory phenotype (SASP) [12]. The
acquisition of this phenotype and consequent phenotypic alterations has broad implica-
tions in health and disease [13]. As with normal cells, cancer cells can be modified to
become senescent. Indeed, comprehensive understanding of this dynamic and complex
process can be exploited as a potential therapeutic intervention to induce senescence in
cancer cells and/or eliminate these senescent cells via a new class of agents known as
“senolytics” and hence cease progression and metastasis of cancer. Furthermore, senescent
cells profoundly affect tissue homeostasis, interfere with organ function, affect other cells
in their environment and a similar process occurs in cancer tissues. Consequently, new
therapeutics with excellent potential can be developed to induce cancer cell senescence,
particularly, in resistant and metastatic cancer.
The era of senolytics is still in its infancy and senolytic agents tested to date include
Dasatinib (D, an FDA-approved tyrosine kinase inhibitor), Quercetin (Q, a flavonoid present
in many fruits and vegetables), Navitoclax, A1331852 and A1155463 (Bcl-2 pro-survival
family inhibitors) and Fistein (F, a flavonoid). Cardiac glycosides, such as digoxin, which
is currently used to treat irregular heartbeat in atrial fibrillation, have also been reported
to have broad senolytic activity [14,15]. Such senolytic compounds have been reported to
function by momentarily restricting the pro-survival linkages that protect senescent cells
against apoptosis without adversely impeding proliferating or quiescent, differentiated
cells [16,17]. Pre-clinical animal studies have indicated that senolytics have potential clinical
utility as they can eradicate senescent cells thereby mitigating age and senescence related
disorders and consequently enhancing healthspan and lifespan [16–20]. Moreover, the
results of the first human clinical trial employing senolytics have been reported. From these
results, it is evident that patients with idiopathic pulmonary fibrosis, a cellular senescence-
driven fatal disease, displayed improved health function after treatment with combination
senolytics therapy (Dasatinib + Quercetin) [21]. Preliminary data from another recent study
has shown that this same combination of senolytics therapy was able to reduce senescent
cells in patients with diabetes mellitus and chronic kidney disease [22]. These studies
highlight the exciting promise and potential utility of senolytics for the clinical treatment of
age related and senescent associated diseases including the potential translation to cancer
and potentially COVID-19.
Even though aging is a major risk factor for COVID-19, the exact role of senescence in
COVID-19 is not fully understood. Further research and studies are required to fully explore
disease mechanisms and elucidate biological factors which may drive immunosenescence
particularly in the elderly in the context of COVID-19. Furthermore, the timely assessment
of COVID-19 severity is critical so that adequate treatments can be administrated rapidly
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to patients. Currently, there is a lack of definitive parameters which can be utilized to
identify patients who are at high risk of requiring admission to intensive care unit (ICU).
Many studies are focusing on identifying such biomarkers for this use. Indeed, changes in
neutrophil-to-lymphocyte ratio and urea-to-creatinine ratio have emerged to have clinical
utility as stand-alone parameters in being able to identify patients with aggressive disease
at an early stage [23]. Currently, there are no such senescence-aging related biomarker
signatures which have been identified for the purposes of risk stratification of severity for
COVID-19 patients. Early intervention and early stratification of patients via such novel
biomarker signatures will inevitably improve clinical outcomes for patients. As COVID-19
research is still very much in its infancy, further studies are needed to explore, identify,
and validate potential novel stratification signatures which have robust clinical utility to
identify risk of severe infection versus non-severe infection and also to help recognize
patients who are higher risk of requiring ICU admission versus those patients who can
be treated in non-intensive care wards. In this review, we will discuss the features of
cellular senescence, the involvement of senescence in cancer and the role of the telomere
clock in aging. The review also discusses the potential association between senescence,
aging, immunosenescence and vaccination (Figure 1) in the context of the global COVID-19
pandemic.




Figure 1. Senescence and Immune Dysregulation in COVID-19. SARS-CoV-2 infection and vaccination are both associated 
with major immunological alterations. These are linked to both aging and senescence. The pathological hyperinflamma-
tory response evident in SARS-CoV-2 infection and the sub-optimal antibody immune responses following vaccination 
against SARS-CoV-2 may be regulated by novel senescence signatures. Identification of novel senescence signatures in 
combination with applied machine learning techniques and the Horvath Clock may help to identify novel senescence 
signatures that may accurately differentiate severe COVID-19 patients from patients with mild to no symptoms (non-
severe). It may also identify novel senescence signatures which are implicated in the waning antibody responses evident 
following vaccination and booster vaccinations. Figure generated using Biorender.com accessed on 17 November 2021. 
2. Molecular Features of Senescent Cells 
When cells become senescent, they undergo a plethora of significant characteristic 
changes including permanent, irreversible cell cycle arrest, morphological, metabolic 
changes, epigenetic, transcriptional as well as chromatin remodeling, metabolic repro-
gramming, altered gene expression, altered microRNA (miRNA) expression and the 
adoption of a pro-inflammatory phenotype commonly known as SASP [12]. These pheno-
typic alterations, which can be inter-dependent, are evident across the various stages of 
the senescent process including senescence initiation, early senescence, and late phases of 
senescence. Even though these features can be inter-dependent, for simplicity, these are 
described separately in the following sections. Senescence is a cellular stress response trig-
gered by molecular damage, such as that caused by replicative exhaustion, aberrant on-
cogene activation (oncogene-induced senescence, OIS), or treatment with chemotherapeu-
tics. Senescence can also be triggered in terminally differentiated cells such as neurons 
[24–26], and cardiomyocytes [27,28]. There are various types of senescence ranging from 
physiological senescence (e.g., embryonic development, wound healing, tissue remodel-
ing, tumour protection, brain homeostasis), replicative senescence (e.g., telomere shorten-
ing and telomere length-dependent limit of cell divisions), stress-induced premature 
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2. Molecular Features of Senescent Cells
When cells become senescent, they undergo a plethora of significant characteris-
tic changes including permanent, irreversible cell cycle arrest, morphological, metabolic
changes, epigenetic, transcriptional as well as chromatin remodeling, metabolic reprogram-
ming, altered gene expression, altered microRNA (miRNA) expression and the adoption of
a pro-inflammatory phenotype commonly known as SASP [12]. These phenotypic alter-
ations, which can be inter-dependent, are evident across the various stages of the senescent
process including senescence initiation, early senescence, and late phases of senescence.
Even though these features can be inter-dependent, for simplicity, these are described
separately in the following sections. Senescence is a cellular stress response triggered by
molecular damage, such as that caused by replicative exhaustion, aberrant oncogene activa-
tion (oncogene-induced senescence, OIS), or treatment with chemotherapeutics. Senescence
can also be triggered in terminally differentiated cells such as neurons [24–26], and car-
diomyocytes [27,28]. There are various types of senescence ranging from physiological
senescence (e.g., embryonic development, wound healing, tissue remodeling, tumour
protection, brain homeostasis), replicative senescence (e.g., telomere shortening and telom-
ere length-dependent limit of cell divisions), stress-induced premature senescence (e.g.,
activation of oncogenes, inhibition of tumour suppressor genes, DNA damage, reactive
oxygen species (ROS), metabolic stress, epigenetic stress, nucleolar stress, telomere inde-
pendent) and drug-induced senescence (e.g., Cyclin-Dependent Kinases (CDKs) inhibitors,
Histone Deacetylase (HDAC) inhibitors, Protein Kinase C (PKC) activators, genotoxic
drugs) [12,29].
The main drivers instigating senescent growth arrest are the CDK inhibitors (CDKi)
encoded in the CDKN2A (p16INK4a), CDKN2B (p15INK4b) and CDKN1A (p21CIP1) loci.
It is well documented that the expression levels of these drivers are known to deviate de-
pending on the phase of senescence and are subject to changes with progression to different
phases of senescence [30–38]. Morphological changes evident in senescent cells have also
been well documented and include the cells becoming enlarged, flattened, vacuolized, ac-
cumulation of lysosomes and mitochondria, altered composition of the plasma membrane,
and sometimes they may feature enlarged or multiple nuclei and cytoplasmic bridges, such
changes are controlled by various different proteins [39–47]. Metabolic changes evident
in senescent cells and which have also previously been reported include augmented gly-
colysis, lysosome biogenesis, mitochondrial metabolism, and autophagy. Indeed, studies
have highlighted that inhibition of autophagy enables the senescence phenomenon, and
decreased autophagic activity in various tissues has been reported to be associated with
aging. Autophagy therefore acts as both a biomarker of aging and a popular anti-aging
target [48–54].
Epigenetic modifications, chromatin rearrangements and global elevations in chro-
matin accessibility have been frequently reported in senescence [55–59], this includes the
formation of senescence-associated heterochromatin foci (SAHFs) [29,59–64], senescence-
associated distension of satellites (SADSs) [56,65] and retro-transposable elements [56,66],
all of which are implicated in senescence. The visual observation of such SAHFs for exam-
ple can be deemed somewhat valuable for identifying senescence however the conservation
across cells and functional significance of these global chromatin alterations remains to be
elucidated [32,67,68] therefore they cannot be used alone as a marker indicating senescence
and rather must be considered with a panel of other markers.
Altered gene and microRNA (miRNA) expression can impact and modulate the
senescence process by directly or indirectly targeting key senescence factors including p53,
p21CIP1 and SIRT1 [69,70]. Various studies have identified proteomic and transcriptomic
signatures, many of which include coding and non-coding RNAs, which are implicated in
mediating and altering senescence [30,70–72]. For example, many studies have illustrated
that miR-24 suppresses the cell cycle regulator p16INK4a in many diseases including
osteoarthritis [73] and prostate cancer [74]. MiRNAs also inhibit known suppressors of
senescence including members of the polycomb complexes such as Chromobox Homolog 7
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(CBX7), Embryonic Ectoderm Development (EED), Enhancer of Zeste Homolog 2 (EZH2),
and Suppressor of Zeste 12 (SUZ12) (miR-26b, miR-181a, miR-210, and miR-424) resulting
in p16INK4a depression and induction of senescence [75]. This highlights the potential
promise miRNAs may have as novel therapeutic “senomiRs” for eliminating senescent
cells [76] and thereby alleviating the detrimental impairment caused by senescence in aging
pathologies.
Finally, one of the most extensively exercised biomarkers of senescence and aging
cells, detected in most in vitro and in vivo settings, is senescence associated βeta Galac-
tosidase (SA β-gal) activity which is known to be greatly enhanced in senescent cells due
to the presence of elevated lysosomal substance [77–79]. It is important to note that the
increased lysosomal content however is also a common feature of specific cell types such
as macrophages, Kupffer cells, and osteoclasts [80,81]. This emphasizes the requirement
to use a panel of biomarkers in combination as opposed to relying solely on SA β-gal
activity to distinguish senescence. Ki67, is another frequently used marker to indicate cell
proliferation. Senescent cells permanently exit the cell cycle therefore this marker should
not be expressed in senescent cells [82]. However, contrasting findings which have shown
that Ki67 may be expressed in quiescent cells [83], and also can be expressed in senescent
cancer cells [84]. Again, this highlights the need for an accurate panel of biomarkers for
senescence as opposed to relying on sole biomarkers.
In summary, many biomarkers (e.g., morphological features, SA β-gal staining, p21CIP1,
p16INK4a, heterochromatin (SAHFs & SADSs) and proliferation (Ki-67) markers) must
be used in combination as part of a panel [85], in order to correctly identify and confirm
senescence in cells.
Senescence-Associated Secretory Phenotype (SASP)
Triggers, such as cytokines, activated oncogenes, ROS, and DNA damage evoke a type
of senescence, called stress-induced senescence as a response mechanism with broad impli-
cations in health and disease [13]. In contrast to apoptosis, senescent cells remain viable
for a longer time and exhibit SASP. SASP is a plethora of pro-inflammatory cytokines and
chemokines, responsible for the complex crosstalk between senescent cells and neighboring
cells [86]. The SASP is encompassed with many immune related markers including tumour
necrosis factor (TNF)-α, IL-1α/β, interleukin (IL) -6, IL-8, CC-chemokine ligand (CCL)-2
and various tissue remodeling factors including TGF-β and matrix metalloproteinases
(MMPs) [12,87–90]. Accordingly, the participation of cellular senescence in various patho-
logical processes may not only be explained by reduced proliferation but also, by cell–cell
interactions and the secretion of mediators that affect surrounding cells [91]. The SASP is
often likened to a double-edged sword as it is dynamic in nature [30]. This is because on
one hand, prolonged exposure of SASP inflammatory mediators can consequently result in
the excessive enlistment of damaging immune cells which leads to chronic inflammatory
diseases [92–94]. Conversely, temporary SASP can promote wound healing caused by acute
cellular damage and can also promote immunosurveillance, particularly in the context
of tumourigenesis where they recruit T cells and natural killer (NK) cells [90,95,96]. It is
important to note however, the SASP is generic, context dependent and highly diverse
and is mediated at various levels. This means that the SASP is limited in its capacity as an
unequivocal marker of senescence as no unique form or mechanism of SASP is known to
exist [30,97,98].
3. Senescence and Cancer
Currently within the western world, the life expectancy of the global population
is increasing. Predictions have reported that the global proportion of people aged over
65 years is expected to increase from 18% to 26% by 2041 and the number of people aged
over 85 years will double from 2% to 4% [99]. Concurrent to the increasing life expectancy,
are increasing levels of age-related conditions and chronic disease and disorders. As a
result, lifespan has overtaken healthspan [100,101], and there is an overwhelming burden
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of chronic health complications and conditions [102] present within the older population,
with over half of people over 75 years experiencing at least 2 or more chronic health
conditions [99]. One of these most common age-related chronic health conditions is cancer.
Cancer is known to be more prevalent in the older population and estimates report that
there will be significant escalations worldwide in the next 15 years and this will be driven
by the aging population and increased life expectancies [103].
Aging and cancer are connected to each other via extensive overlap of several molecu-
lar pathways and causes implicated in aging [104], and those also involved in cancer [105].
Aging is pivotal to the causality of numerous cancers and is known to influence several
aspects including response to therapy, provision of therapy, tolerance to therapy and prog-
nosis. Therefore, one of the most fundamental factors in the aging process, referred to as
senescence, links both the aging and cancer phenomena together. It is thought that senes-
cence has a predominant tumour suppressive function by limiting aberrant or excessive
cell proliferation [106], however it has been reported that the acquired SASP and resultant
alterations in the cellular microenvironment of senescent cells may in fact promote and
encourage tumour progression, tumour recurrence and SASP programming may indeed
drive cancer-therapy induced senescence of tumour and non-tumour cells [44,107–111].
This next sections of this review will endeavour to link both aging and senescence in the
context of a very relevant and new disease, COVID-19.
4. The Potential Implications and Clinical Translation of Senescence & Aging
in COVID-19
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), which has a fundamental role in regulating gene expression and viral pathogenicity.
COVID-19 has resulted in a pandemic associated with substantial morbidity and mortality
worldwide. The identification of diagnostic/prognostic biomarkers and therapeutic targets
is therefore critical in directing the pandemic. The link, if it exists, between senescence,
aging and COVID-19 is an extremely novel area of research, has not been extensively
studied and therefore remains an open question.
Epidemiological studies to date have shown that COVID-19 has a high mortality
especially in patients of advanced age and those with comorbidities such as cardiovascular
disease, diabetes, high blood pressure, chronic obstructive pulmonary disease, asthma,
and cancer are much more susceptible to developing severe COVID-19 disease [112–115].
Cellular senescence can be prematurely stimulated by viral infections. Some viruses can
activate senescence via DNA damage [116], or cell fusion [47]. This suggests senescence
may have a key role in many viral infections.
Currently, COVID-19 research using proteomics and transcriptomic analyses are
focusing on identifying and validating prognostic, diagnostic and prediction markers
which are more robust and reliable than current inflammatory markers. Studies are also
working to establish if the presence of specific biomarkers make a patient more susceptible
to a more severe infection. The identification of such biomarkers could help predict the
severity of infection expected and therefore could help determine in advance the level
of medical intervention that would be much more beneficial and could be administered
much faster to the patient. For example, a recent study has reported that long pentraxin 3
(PTX3) is an independent strong prognostic indicator for predicting mortality in COVID-
19 and is a superior biomarker compared to conventional inflammatory markers [117].
Conversely, another study disputed this finding and has suggested that PTX3 is not
any more valuable than other markers and that there are more important markers of
inflammatory pathways [118]. Another study has reported that Growth Differentiation
Factor 15 (GDF-15) is increased in patients who are hospitalized with COVID-19 and
higher levels are associated with a worse outcome. Again, this biomarker was reported to
be superior to routinely used cardiovascular and inflammatory biomarkers [119]. Other
studies have also identified several differentially expressed proteins which are specific to
COVID-19 severity [120–123]. As discussed previously, telomere shortening is associated
with senescence. A recent study has reinforced the idea that senescence is linked to COVID-
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19, by establishing that patients who possessed shorter telomeres have an elevated risk of
developing severe COVID-19 pathologies [124].
It is therefore likely that a combination of biomarkers will be required as opposed to
individual biomarkers for accurately predicting COVID-19 clinical outcomes. Senescence
markers could be combined with patient phenotypes to identify patients that might develop
severe COVID-19 or predict those who will go on to have post COVID-19 syndrome,
referred to as Long COVID. They may also help understand the immune response to
both SARS-CoV-2 infection and vaccination. Long COVID is defined as having signs
and symptoms post COVID-19 infection which continue for greater than 12 weeks and
cannot be explained by alternative diagnoses. It is recognized as an evolving problem
with substantial potential to impact healthcare and economics on a worldwide and longer-
term basis. Patients with Long COVID have been reported to present with ongoing
symptom burden such as persistent breathlessness, cough and fatigue, elevated blood
biomarkers such as d-dimer and C-reactive protein (CRP) levels, have changes in lung
function and deteriorating chest imaging which could lead to lung fibrosis [125–129]. The
reasons as to why some people develop Long COVID is poorly understood, and further
studies are mandated to identify drivers which predispose individuals to developing this
debilitating condition. As postulated throughout this review, we propose that senescence-
aging-COVID-19 are clearly linked even though the relationship and mechanisms are
not yet fully apparent. We also propose that it may be possible that the development
of Long COVID is also implicated within this loop; studies will be required to further
explore this likelihood. The identification of hallmarks of potential senescent endotypes (or
“sendotypes”) could be therapeutically exploited for drug discovery to alleviate COVID-19
symptoms, both during and post SARS-CoV-2 infection (Figure 2). Machine learning
techniques could be applied in conjunction with the Horvath Clock and clinical data to
identify novel secretory senescence signatures to yield sendotypes that may accurately
differentiate severe COVID-19 patients from patients with mild to no symptoms. The next
sections of this review will focus primarily on the associations between aging, senescence,
immunosenescence and vaccination in COVID-19.
4.1. Aging and COVID-19
The global pandemic of COVID-19 was declared on 11 March 2020 by the World Health
Organization (WHO). As per the WHO statistics, as of 17 September 2021, there have been
226,844,344 confirmed cases of COVID-19 including 4,666,334 deaths [130]. COVID-19
can present as asymptomatic or symptomatic, with the main symptoms including fever
(high temperature: 38 ◦C or above), a new cough, shortness of breath, fatigue, loss or
change to your sense of smell or taste and gastrointestinal symptoms. More severe cases
of SARS-CoV-2 infection may manifest into viral pneumonia-induced acute respiratory
distress syndrome (ARDS) and are associated with mortality and age [112,131]. Most
cases of SARS-CoV-2 infection present as mild to moderate illness and some people do
not have any clinical manifestations at all from SARS-CoV-2 infection [132,133]. Such
individuals who present as asymptomatic are therefore deemed as a major sources of virus
spread [132,134]. A study reported in New York illustrated that out of 141,495 patients
tested, 33% of the patients tested positive for COVID-19, many of these positive cases were
asymptomatic patients [135]. Thus, the extent of asymptomatic infection and asymptomatic
spread is potentially a major confounding factor in controlling the global pandemic. Indeed,
the silent spread of COVID-19 worldwide will ultimately increase transmission amongst
all individuals and especially to the more elderly populations who are already prone to
a higher risk of more severe infections and complications [136,137]. The development
and implementation of various public health measures including contact tracing and
prediction/forecasting models may help to address this alongside artificial intelligence and
machine learning technologies [138–140].
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COVID-19 is recognized as having a heterogeneous nature and therefore a diverse
plethora of host factors are fundamental in determining the severity and progression of
the disease in which a patient may acquire [133]. Some of the major risk factors associated
with acquiring severe SARS-CoV-2 infection include age, male gender, smoking, chronic
obstructive pulmonary disease (COPD), obesity, asthma and underlying comorbidities in-
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cluding chronic health conditions such as hypertension, diabetes, and cancer [115,141–143].
Indeed, significant evidence from across the world strongly advocates that age is the most
important determining risk factor for severe COVID-19 disease [144], and its adverse
health outcomes including hospitalization, moderate or severe pneumonia, severe ARDS,
cardiovascular complications, kidney injury, stroke, ICU admission and death [145–148].
The following paragraphs presents the data from around the world which support the
hypothesis that COVID-19 is an emergent disease of aging.
China was the first country to report SARS-CoV-2 infection amongst its population.
Early data from China indicated that the case fatality ratio (CFR) of COVID-19 increases
with age. It was reported that the CFR for patients aged 40 years or less was lower than
0.4%, the CFR increased to 8% for patients in their 70’s and further increased to a staggering
14.8% in patients aged 80 years and above [141,149]. Italy also reported the same profound
effect of aging in its COVID-19 CFR data where the CFR was lower than 0.4% for patients
aged 40 years or less and increased to a CFR of 12.8% for patients in their 70’s and further
increased to a CFR of 20.2% for patients in their 80 s and above [131]. Moreover, the
overall CFR in Italy was much higher than China, 7.2% vs 2.3%, respectively, which may be
explained by the fact that Italy has one of the highest proportions of elderly adults in the
world. Similar findings were also reported confirming this strong link between COVID-19
CFR and aging across various different countries where the CFR for COVID-19 was shown
to increase exponentially with age [150]. In a separate retrospective study of 1591 patients
in Italy, it was reported that the median age of patients critically ill with COVID-19 was
63 years old [136].The COVID-19 data reported by the US Center for Disease Control and
Prevention (CDC) on 15 September 2021 also demonstrates that the older age group of
65 years and above accounted for 77.7% COVID-19 deaths compared to the lower age
group of 45 years or less which accounted for only 3.3% COVID-19 deaths [151], again
highlighting age as the major determinant factor in COVID-19 mortality.
Indeed, patient age is reported to contribute to the risk of COVID-19 incidence and
severity [152]. Nursing homes (NHs) globally have been detrimentally affected with
COVID-19 outbreaks and as a result, these settings are associated with increased mortality
linked to COVID-19. This is mainly due to the fact that patients within NHs commonly
are usually older in age, have comorbidities and tend to be frailer, thus highlighting the
importance of evaluating frailty status [via the Multidimensional Prognostic Index (MPI)],
to help stratify prognosis for COVID-19 patients [153]. Several studies have reported that
SARS-CoV-2 infection is associated with a higher risk of mortality than those patients not
affected by COVID-19 within NHs [153]. The most striking evidence is the data reported on
COVID-19 cases and death in NHs across the US. This comprehensive analysis updated by
The New York Times on 01 June 2021 indicated that there are up to 1.5million NH residents
in the US, approximately 0.5% of the total US population. Stark figures have demonstrated
that 4% of the confirmed COVID-19 cases in the US was found to be amongst these vulner-
able and frail elderly patients. Sadly, they accounted for 31% of the COVID-19 fatalities in
the US [154]. This is similar to other countries where NHs accounted for 41% COVID-19
deaths (based on 22 countries) even though they house only a small proportion of the
total population [155]. Furthermore, it is important to establish the specific characteristics
which make certain NH residents more susceptible to mortality from SARS-CoV-2 infection.
One study reviewed 5,256 US NH residents who had acquired SARS-CoV-2 infection and
found that increased age along with other features including male sex, impaired cognitive
and physical function were independent risk factors for 30-day mortality [156]. Other
studies also report similar findings highlighting specific characteristics and prognostic
factors for mortality in COVID-19 positive elderly patients, these studies highlight the
need for early diagnosis and individualized therapeutic management for elderly patients
considering their medical history and polypharmacotherapy [144,153].
Overall, taken together, the current epidemiological data indicates that COVID-19
patients aged >80 years illustrate a higher risk of mortality compared with younger pa-
tients [115,131,144]. As the evidence demonstrates, age is considered to be one of the single
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biggest factors in COVID-19 with underlying comorbidities and chronic health conditions
found in higher abundance in the aged. Therefore, this predisposes them to a higher risk of
more severe COVID-19 disease and poorer clinical outcomes. Another aspect of concern is
the impact of vaccination and how age is also implicated, this will be discussed later in this
review.
4.2. Senescence and COVID-19
As mentioned in previous sections, senescence is the phenomenon which describes
the state when cells stop proliferating and enter permanent cell cycle arrest. A multitude
of biomarkers must be used to correctly identify senescent cells. A major age-associated
hallmark is the accumulation of senescent cells with the acquirement of the SASP. The next
sections will endeavor to highlight how senescence and the process of biological age, rather
than chronological age, is perceived as a potential mediator in COVID-19 pathogenesis
and severity. Studies are required to identify functional mechanisms which link SARS-
CoV-2 infection, COVID-19, and biological aging. Addressing this may potentially provide
attractive avenues for therapeutic targets to alleviate COVID-19 disease severity, this is of
particular interest for the elderly who are most vulnerable and susceptible.
During aging and chronic disease, senescent cells are allowed to accumulate and are
not removed via immune regulation or apoptosis processes. Aged tissues are also prone to
damage and thus are more likely to enter into senescence [92,157–160]. Cumulatively, these
events give rise to the continual buildup of senescent cells with age and the initial benefit
is quickly replaced by detrimental functions which are primarily induced by the persistent
secretion of SASP factors, malfunction of processes within tissues, atypical propagation of
paracrine senescence and chronic inflammation. Consequently, the process of senescence
compromises tissue repair and regeneration and ultimately contributes towards the aging
process. As mentioned already, it has been reported that the eradication of senescent
cells via senotherapies, in aged or chronic diseases, can alleviate the commencement and
advancement of age-associated dysfunctions and pathology and ultimately help to extend
health span [21,22,161–164]. Studies have shown that viral infection in cells can induce
cellular senescence [47,116]. The initiation of senescence can be mediated directly or
indirectly by elevating IFNs secretion from viral infected cells [165], and via the discharge
of damage-associated molecular patterns (DAMPs) from cells enduring inflammatory cell
death [166]. Indeed, extended exposure to IFN-γ and IL-6 was demonstrated to activate
senescence within the surrounding environment via SASP factors [167,168].
One of the principal elements of SARS-CoV-2 infection is the consequent reaction of
the patient’s immune response to the virus and the subsequent multi-organ inflamma-
tory response. Aging is associated with weak and less effective immune responses; this
phenotype is defined as “immunosenescence”. The acquirement of this phenotype in the
elderly predisposes them to complications instigated by viral infections [169]. A significant
correlation between age and SARS-CoV-2 viral load has been demonstrated [170,171]. Viral
infection via SARS-CoV-2 triggers a dysregulated reaction referred to as the “cytokine
storm” during the early stage of infection. During the cytokine storm, an array of inflam-
matory cytokines and chemokines such as IL-6, IL-8, IL-12, IL-1β, CXCL-10, CCL-2, IFN-γ,
and TNF-α are emitted. Several of these inflammatory molecules have the capacity to
instigate “paracrine” senescence via a persistent cytokine signaling [112,167,168,172,173].
Infection via the SARS-CoV-2 virus is thought to instigate inflammatory cell death other-
wise known as pyroptosis [174]. Even though, an immune response is normal to curtail an
infection, evidence is showing that excessive levels of such cytokines and inflammatory
regulators is correlated with poorer outcomes. For example, elevated levels of various
markers including serum ferritin, prothrombin time, lactate dehydrogenase, and IL-6 have
been linked with mortality in COVID-19 patients [115]. Findings have also shown that
increased levels of cytokines have been reported in COVID-19 patients compared to healthy
patients. Deeper analyses also revealed that specific concentrations of some markers includ-
ing IL10, GCSF, IP10, MCP1, MIP1A, and TNFα were elevated in ICU COVID-19 patients
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compared to non-ICU patients [114]. This massive cytokine storm apparent in infection,
in conjunction with altered anti-inflammatory functions, may contribute to an imbalance
in the coagulation axis consequently impacting on severity and leading to fatal clinical
outcomes [175–179]. These manifestations are phenotypical of immunosenescence, and
these will be discussed further in the next sections of this review.
In brief, it is expected that patients of increased age have a higher probability of
accumulating high levels of cellular senescence. The rationale behind this is that the
proportion of senescent cells is already increased prior to the time of SARS-CoV-2 infection
thus may accelerate paracrine senescence events. Older cells are also more prone to
becoming senescence due to the reduced ability to restore impairments. Finally, an aged
immune system is less competent in its ability to eradicate senescence cells, this is partially
due to a deterioration in immune functionality. This may explain why older patients are
more susceptible to SARS-CoV-2 infection and at a higher risk of more severe COVID-19
disease and mortality. It is thought that inhibition of SASP or reducing senescent lung
cells via senolytics may be more beneficial in elderly people with COVID-19. This is
a hot topic and new research findings may have a significant translational impact on
patients by identifying novel senescent biomarker signatures which have the potential to
change the way we predict COVID-19 severity. This may provide exciting avenues for
therapeutic intervention by targeting senescence-associated mechanisms via senotherapies
in COVID-19 patients and may also serve to help enhance vaccination efficacies.
4.3. Immune Dysregulation during COVID-19
SARS-CoV-2 infection activates both innate and adaptive immune responses. In at
risk individuals, with diminished anti-viral defenses, an excessive immune response can
develop which is associated with aberrant inflammation and increased disease sever-
ity [179,180]. This immunopathological response can exacerbate comorbid conditions,
spark disproportionate clotting and cardiovascular complications, and cause persistent
symptoms such as fatigue and depression. In severe disease subgroups immune system
dysregulation is evident; elevated plasma cytokine levels are accompanied by reduced T
lymphocyte numbers (especially CD4+ and CD8+ T cells), accumulation of neutrophils,
fever, platelet deficiency, elevated ferritin, and elevation of other inflammatory and clotting
factors [112,177,181]. Our knowledge of the discrete mechanisms and signatures of the
pathological immune response and its impact upon the development and persistence of
protective immunity is developing at pace with longitudinal, immunological, omics and
systems biology approaches.
Immunological responses detected post-SARS-CoV-2 infection are highly variable,
though appear to be associated with severity and influenced by age and comorbidities.
Patients with severe disease tend to have higher antibody titres than those with mild
disease, possibly due to higher viral load [182]. Older age groups where the immune
system is often functionally impaired also tend to have elevated antibody titres, though
the functional quality and durability of protection is unknown [182–185]. Also male, older,
and obese patient groups tend to have higher background inflammation and lower T cell
subsets, these are already known to be depleted in severe COVID-19, the presence of
these characteristics may therefore increase susceptibility to SARS-CoV-2 and predisposes
individuals to more severe disease [186]. Furthermore, the level of T cell response appears
to be important, as poor T cell immunity correlates with severity and potentially short-lived
protective immunity [187].
Transcriptome wide analyses of blood from severe COVID-19 patients reveals a series
of activated immune system genes including those associated with neutrophils, secretory
granules, neutrophil extracellular traps (NETS) along with clonal expansion of adaptive
immune response and diminished lymphocyte gene expression [188]. The following
sections provide an overview of the exuberant innate and poor adaptive immune responses
and subsequent cytokine storm and tissue damage sequalae observed in severe cases of
COVID-19.
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4.3.1. Innate and Adaptive Immune Responses in the Pathogenesis of COVID-19
Initial innate system Type I and III interferon responses are suppressed or disrupted
which results in early IL-6, IL-10 and IL-1β enhanced inflammation [189]. It has been
postulated that SARS-CoV-2 along with other coronavirus’ show genome patterns (signif-
icant under-representation of CpG dinucleotide pairs) associated with diminished viral
recognition and dysregulated immune response [190]. The ensuing inflammation is propa-
gated by aberrant monocytes, macrophages, and NK cells in their attempt to send viral
pathogen-associated molecular patterns (PAMPs) and DAMPs into affected tissues. This
results in neutrophil-driven pathology including fibrosis that causes ARDS. Activated
leukocytes and neutrophil extracellular traps (NETs) also promote abnormal clotting which
accumulates in lung and kidney tissues of patients with severe COVID-19 [191,192]. Nu-
cleocapsid and spike proteins of SARS-CoV-2 are thought to play a central role in driving
NET formation [193]. Treatments that target inflammation and coagulation may therefore
reduce COVID-19 mortality.
CD4+ and CD8+ are an important part of the antiviral adaptive immune response to
SARS-CoV-2 infection. The quality and breadth of CD4+ and CD8+ T cell response plays a
key role in COVID-19 resolution and modulation of disease severity. B and T cell depletion
are early indicators of severe disease development and along with markers of liver damage,
act as predictors of mortality in severe COVID-19 patients [194]. Regulatory T-cells on the
other hand control immune system homeostasis and self-tolerance by negative regulation
of effector functions, activation, and proliferation of immune cells [195]. Increased Notch 4
expression on circulating regulatory T cells (Tregs) promotes inflammation and diminishes
repair of lung tissue and again predicts mortality in those severely affected by COVID-19
and in convalescent patients who exhibit reduced levels post recovery [196].
In recovered COVID-19 patients and in terms of resultant protective immunity, an
integrated study of SARS-CoV-2 immune memory in a longitudinal cohort over 8 months
exhibited distinct kinetics [184]. Immunoglobulin G (IgG) to the spike protein is relatively
stable over 6 months. Spike-specific memory B cells are more abundant at 6 months than
at 1 month after symptom onset. SARS-CoV-2 specific CD4+ T cells and CD8+ T cells
decline with a half-life of 3 to 5 months. Investigations of T cell reactivity across the entire
SARS-CoV-2 proteome reveal distinct patterns of immunodominant S, N, and M protein
regions for CD4+ T and CD8+ T cells [197]. Tarke et al. also found negligible impact
of mutations found in SARS-CoV-2 variants upon CD4+ and CD8+ responses in those
recovered from COVID-19 or mRNA vaccination [198]. Persistent symptoms also do not
adversely impact SARS-CoV-2 specific T cell-based immunity [199].
4.3.2. The Cytokine Storm and its Association with COVID-19
There is continued debate around the role of the so-called “cytokine storm” in COVID-
19 pathophysiology and severity [200]. Albeit there is irrefutable evidence of increased
systemic levels of pro-inflammatory cytokines in subsets of patients with COVID-19, ele-
vated cytokine response is more consistent in other acute conditions such as sepsis, trauma,
and cardiac arrest. Imbalanced cytokine responses for example, rather than magnitude
of cytokine storm may contribute to cardiac dysfunction in juvenile multisystem inflam-
matory syndrome (MIS) [201]. A tissue wide systems immunology-based study reveals
that the cytokine storm triggered by SARS-CoV-2 infection may result from dysregulated
cytokine production by inflamed pulmonary, heart, liver, and kidney tissues [202]. Further
studies are warranted to further explore the association between COVID-19, immune
dysregulation, and cytokine storm.
4.4. Immunosenescence and COVID-19 Severity and Mortality
Immunosenescence is a distinctive feature of aging and is associated with defective
immune responses and thus less effective anti-viral responses. As individuals get older,
there is aberrant interruption of both the innate and adaptive immune responses along-
side chronic inflammation due to recurrent production of inflammatory mediators and
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cytokines, also referred to as “inflammaging”, thereby predisposing the elderly to com-
plications during viral infections [169,203,204]. Immunosenescence has pleiotropic effects
on the immune system and changes observed can be attributed to numerous intrinsic and
extrinsic factors. Immunosenescent phenotypic manifestations include dysregulation of
innate immunity and cytokine production, loss of naïve T cells, accumulation of terminally
differentiated memory T and B cells, deterioration in the function of T and B cell function
and decreased lymphocyte proliferation [205–207].
There are limited studies on the role of cellular senescence and specifically immunose-
nescence in COVID-19. Recent findings have however shown that there is the presence of
an immunosenescent phenotype which appears to be underpinned by elevated neutrophils-
to-lymphocytes ratio (NLR) [208], and high IL-6 production [209], and is correlated to
disease severity [210]. For example, a recent study has reported that a Th2/Th1 cytokine
imbalance is correlated with a higher risk of mortality from COVID-19 [211]. Findings
from another study have reported that biological age measure [on 42 biomarkers] captured
using PhenoAge, as opposed to chronological age, is responsible for pushing the trends
and correlations we are seeing with COVID-19 severity and age. This study reported
that accelerated aging 10-14 years prior to the COVID-19 pandemic was linked with test
positivity and mortality from SARS-CoV-2 infection [212], thus highlighting that COVID-19
severity can be predicted by earlier evidence of accelerated aging. It is also thought that
polymorphisms of the STING (stimulator of IFN genes, encoded by TMEM173) pathways
could be implicated in COVID-19 pathogenesis [213]. Findings have shown that STING
aberrations are correlated with risks of aging-related disorders. Specifically, the STING
p.R293Q offers protection both from inflammaging and obesity-associated cardiovascular
disease in advanced age individuals [214]. This may suggest that overload of the STING
pathway may contribute towards COVID-19 severity in the elderly and also may explain
complications associated with COVID-19 including myocardial infarction. Data however
is limited, and it remains poorly understood if senescent cells are friends or foes in viral
infections and further studies are warranted to fully explore this relationship [215].
4.5. Senescence Involvement in Multimorbidity and COVID-19
Many hospital programs and services for treatment of health conditions within pa-
tients has been detrimentally destabilized due to the COVID-19 pandemic. In particular,
cancer services including elective surgeries have been severely disrupted. There is now a
tsunami of patients on extremely long waiting lists. Such emergency and elective surgery
programs need to be separated from the COVID-19 pandemic and need to instead run in
parallel. Multimorbidity (multiple long-term conditions) is defined as two or more diseases
(usually >5) occurring simultaneously in an individual (usually increasing in number with
age) [216], necessitating multiple treatments simultaneously. One of the greatest challenges
that healthcare services face is developing optimal treatments for such patients as well as
implementing new strategies and approaches to deal with the increased demand. These
challenges are further exacerbated by an aging population, due to increased life expectancy
which equates to increased number of patients living with multimorbidity who are seeking
treatments [99]. Medical advancements have increased the lifespan but with intensifying
levels of chronic disease burden and increased treatment demands, research now needs to
focus on enhancing healthspan alongside lifespan.
COVID-19 is an emergent disease of aging and poorer clinical outcomes are evident
in patients with existing comorbidities [113,145,150]. Even though older and multimor-
bid patients represent the highest risk group, they have been excluded from the current
COVID-19 vaccine trials. This exclusion of the most vulnerable will undermine and raise
trivial questions as to the applicability and relevance of clinical trial data to these highest
risk patients [217]. Indeed, the identification of high-risk patients in the context of their
age and multimorbidity profile can be used to define potential interventions of selective
confinement or unique management [218]. In addition to age, other conditions, such as cor-
tisol excess in COVID-19 for example, are risk factors which may expose patients to having
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worse clinical progression following SARS-CoV-2 infection [219]. Indeed, implementation
of education strategies for high-risk patients who have such conditions, in conjunction with
enhanced medical management solutions such as performing clinical triage to prioritise
medical consultations and digital telehealth solutions will help with self-management
strategies to prevent complications and disease transmission.
The intricate means by which the phenomenon of senescence contributes to multiple
long-term conditions is not yet known. We therefore hypothesise that specific sendotypes
may indeed act as differentiating factors in multimorbid diseases as well as in COVID-19
and may have potential to act as therapeutic targets for intervention. We also postulate
that senescence may be involved in driving more severe COVID-19 especially in elderly
patients burdened with multimorbidity.
4.6. Senescence Involvement in Vaccination and the Association with COVID-19
Vaccination against COVID-19 unified scientific communities globally as they raced
together to identify therapeutic and preventative solutions including the identification and
development of viable vaccine candidates to stem the threat of COVID-19 worldwide. There
are now several vaccines which are in use across the globe, including the Pfizer-BioNTech
messenger RNA (mRNA) vaccine, BNT162b2 and the Oxford-AstraZeneca adenovirus
vector vaccine, ChAdOx1-S, which were approved for emergency use [220,221] by the
Medicines and Healthcare products Regulatory Agency (MHRA)As reported by the WHO,
as of the 15 September 2021, a total of 5,634,533,040 vaccine doses have been administered
worldwide [130]. Vaccinations are administrated to the muscle where there is an abundance
of senescent cells in correlation with increased age [222,223], this potentially may be a
factor which may contribute to waning vaccine efficacy over time, especially in the elderly.
4.6.1. Initial Vaccination Efficacies
The COVID-19 vaccines currently available have demonstrated very high levels of
efficacy during the clinical trials and these levels of efficacy are being continuously moni-
tored and analyzed as new SARS-CoV-2 variants of concern (VOC) and variants of interest
(VOI) emerge. Seropositive SARS-CoV-2 patients are projected to have 89% protection from
reinfection [224], whilst reported vaccine efficacies range from 50-95% [225]. For example,
the clinical trial of the COVID-19 mRNA vaccine BNT162b2 (Pfizer-BioNTech Vaccine)
observed that two doses of the vaccine can confer 95% protection against COVID-19 in
patients aged 16 years and over [226]. Indeed, other data has shown that one dose of
either the BNT162b2 or the ChAdOx1-S (Oxford-AstraZeneca Vaccine) provides ~60-70%
protection against symptomatic COVID-19 and also offers ~80% protection against hospital
admission [227]. All vaccines developed to date are continuously monitored. For instance,
data from four separate clinical trials in the UK, Brazil and South Africa was pooled in an
interim analysis to evaluate the ongoing efficacy of the ChAdOx1-S vaccine. It was found
that the vaccine demonstrated efficacy against COVID-19 across all trials [228].
As elderly individuals are most at risk of developing more severe COVID-19, the
safety and efficacy of vaccines in the elderly is critical to their success. Studies to date on
the efficacy of the vaccines in the elderly individuals have shown promising results. The
administration of one dose of either the BNT162b2 or ChAdOx1-S in elderly patients specif-
ically was associated with a significant reduction in symptomatic COVID-19. Furthermore,
one dose of either vaccine was 80% effective at preventing hospital admission, and notably,
a single dose of the BNT162b2 was 85% effective at preventing mortality in patients with
COVID-19 [227]. This highlights the promise of vaccination for saving lives in the older
population who predominantly are affected with more severe disease.
Clinical trials are also ongoing within some countries to investigate and establish if a
patient can have a first dose from one vaccine and the second dose from a different vaccine.
Preliminary data from a Spanish clinical trial, CombiVacS, of ~600 patients who received
AstraZeneca as the first dose followed by Pfizer as the second dose has been reported.
Results so far indicate, that the mix and match of two different vaccines was able to elicit an
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extremely potent immune response and antibody levels increased dramatically upon the
second dose with Pfizer [229]. This strategy of heterologous prime and boost, which has
been deployed for vaccines against other infectious diseases, such as Ebola [230], shows
the promising potential of using a combined approach. It is questionable however whether
a third booster dose would work to prolong immunity or protect against emerging variants
in this context and if elderly patients would benefit more from this combination vaccination
strategy. More research is required before this can be confirmed.
4.6.2. Emerging Impact of Neutralization Responses to Vaccination
As the vaccines against COVID-19 are relatively new, it is still too early to know the
exact duration of the protection of the vaccine and the level of immunity these vaccines offer
against new emerging variants and also against reinfection. As mentioned already, current
vaccines appear to have excellent efficacy when administered using the two-dose approach
and data published early in 2021 demonstrated that immunological memory in 95% of
individuals was retained for ~6 months after infection [184]. However, data is starting to
now accumulate illustrating the impact of neutralizing responses to vaccination and the
resultant correlation with waning protection in individuals and importantly in the elderly.
Indeed, multiple animal models of COVID-19 have already illustrated that protection
from COVID-19 is largely mediated by the antibody immune response and neutralizing
antibodies [231–233], therefore highlighting the fragility associated with waning immune
response.
Current studies are focusing on investigating these waning immune responses. A re-
cent study has analyzed the association between in vitro neutralization levels and the
apparent protection from COVID-19 infection using data from seven different vaccines
and from different patient cohorts. The study highlighted that neutralization levels are
highly predictive of immune protection in COVID-19 infection and that their prediction
models show that deterioration in the neutralization titre occurs over the first 250 days after
vaccination, resulting in a significant drop in protection from COVID-19, albeit protection
against severe infection should remain [234,235]. Other studies have also found similar
findings that the primary immune responses are inevitably waning [184,236,237], and there
has been a considerable increase in COVID-19 positive cases amongst the unvaccinated
elderly [238,239]. One of the most recent studies has shown that the efficacy of BNT162b2
vaccine declines gradually over a period of 6 months post vaccination. Despite this decline
in efficacy, the study confirms that the vaccine still exhibits a promising safety profile and
still remained highly effective in preventing COVID-19 [240].
There is limited data available on neutralizing antibodies or vaccine efficacy in the
elderly, the most vulnerable older group of patients. Increasing evidence shows that both
humoral and cellular immunity are both vital in fighting against COVID-19 [241]. A group
of proteins known as stress-inducible proteins (sestrins) are known to have a fundamental
role in controlling T cells that possess senescent like characteristics. Previously, it was
shown that the knockout of these sestrins in animals resulted in the production of elevated
levels of neutralizing antibodies against influenza infection [242], whilst other studies
illustrated that the knock down of sestrins was able to restore the function of T cells [243].
This portrays the key function of sestrins in bridging the link between senescence and
immunity. Indeed, it is speculated that cellular senescence may promote a deviation from
adaptive immunity towards innate immune responses in the elderly with a negative impact
on vaccine efficacy. Furthermore, recent studies have indicated that serum neutralization
and binding of the IgG/IgA immune response after the first dose of vaccination decreased
in patients of increased age with the most prominent decline in patients aged 80 years
and above. Moreover, it was apparent that individuals aged 80 years and above had
dramatically decreased or lack neutralization potency against certain SARS-CoV-2 VOC
including B.1.1.7, B.1.351 and P.1 after the first dose of vaccination. However, following
two doses of vaccination, this was no longer evident and neutralization against VOC
was measurable irrespective of age [244]. Studies are further required to specifically
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address the mechanisms behind these diminished levels of neutralization antibodies and
the concomitant diminished protection in the vaccinated elderly. On a contrary perspective,
it is also important to note that SARS-CoV-2 infection in vaccinated individuals was more
likely to present as asymptomatic, especially in those aged 60 years and above [245], this
may have implications for transmission rates and also booster vaccinations.
4.6.3. Future for Booster Vaccination Implementation
Cumulatively, these findings affirm that specific measures such as booster vaccina-
tion campaigns, in the elderly especially, to enhance immune responses may need to be
implemented, particularly where SARS-CoV-2 VOC are imminent. Booster vaccination
programs are already underway in some countries, including Israel. Indeed, preliminary
findings have shown that a third Pfizer booster shot for those aged above 60 years was
able to reduce the risk of infection by 86% and reduced the risk of severe COVID-19 by
92% [246]. Other studies also show that the third booster shot is capable of inducing
vaccine effectiveness increases and restoration of protection in those individuals infected
with the Delta variant [247,248]. Many other countries, including Ireland, UK and the USA
are now also rolling out mass booster vaccination campaigns. Overall, it is evitable, that
booster doses to restore immunity at some stage will be necessary to control the COVID-19
pandemic. However, a key question is, will the third booster dose be enough to protect
the high-risk populations including the elderly, or are we looking at a fourth booster or
even the implementation of annual vaccination schemes similar to that for influenza in the
future.
Studies highlight the utility of neutralization and immune protection prediction mod-
els in developing vaccine approaches to control the future trajectory of the COVID-19 global
pandemic. Neutralization antibody levels wane over time, though this parameter alone is
not specific as a correlate of immunity and must be considered with the innate/adaptive
immune responses and immunological memory. It can be speculated that senescent cells,
which are found at higher abundance in older people [159,160], may be directly or indi-
rectly influencing the immunological memory capabilities of T and/or B cell functions
in the immune response to SARS-CoV-2 infection and vaccination [249]. Findings have
illustrated a negative correlation between CD4/CD8 T-cell ratio and the severity of frailty
in the elderly in viral infection [206,250–252], however, the performance of these cells in
COVID-19 needs to be explored. Previous studies have confirmed that proficient B cells
decrease with age whilst the number of senescent memory CD27-B cells increases in the
elderly [253]. We therefore postulate that there may be an impairment of both effector
memory T cells and efficient B cells during SARS-CoV-2 infection which may reflect the
effectiveness of the vaccination similar to that seen in influenza-like illness where the
effectiveness of vaccines is lower in the elderly compared to younger individuals [254–256].
This plausible speculation however remains to be elucidated.
4.6.4. The Potential Impact from the Emergence of New Viral Variants
The emergence of new viral variants is a persistent concern as they may have increased
transmissibility [257], and they may evade control by both vaccine induced and conva-
lescent immune responses by having reduced sensitivity to vaccine or infection elicited
antibodies [258,259]. Consequently, this may impede clinical efficacy [260], thus ultimately
raising fears for the most vulnerable groups, such as the elderly, where the level and quality
of immune responses may be suboptimal. According to the WHO, there are four VOC to
date, these are referred to as Alpha, Beta, Gamma and Delta [261,262]. The Delta variant is
currently the most dominant variant worldwide and has been identified in over 170 coun-
tries and is recognized as the most dangerous, as it is much more transmissible in nature.
This VOC have been recognized to be less well neutralized by vaccine induced antibod-
ies [263]. One study has illustrated that natural immunity appears to elicit a longer lasting
and more robust protection against SARS-CoV-2 Delta variant infection, symptomatic
disease and hospitalization compared to BNT162b2 vaccine induced immunity [264].
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Furthermore, it has been reported that vaccine effectiveness after one dose of the
vaccine (BNT162b2 or ChAdOx1-S) was markedly lower in those who subsequently became
infected with Delta variant, compared to those with the Alpha variant. This highlights
the importance of sustaining efforts to maximize vaccine uptake of both first and second
doses especially in high-risk populations such as the elderly [265]. Furthermore, although
a small study, it has been reported that the Delta variant appears to be able to partially
evade neutralizing antibodies stimulated by previous infection with SARS-CoV-2 or by
vaccination [266]. Moreover, it has been reported that in NH residents, many of whom
are elderly, vaccine effectiveness during the widespread circulation of the Delta variant
was found to be significantly decreased in patients compared to the pre-Delta variant
period [267]. This again emphasizes that specific prevention measures (e.g., vaccination
amongst staff, visitors, residents, booster vaccinations) to protect high risk populations
such as elderly residents within NHs are absolutely critical in order to optimize protective
immune responses and ultimately save lives. This raises fears for the high-risk populations
albeit more studies are required to fully comprehend the role of such humoral responses in
the efficacy of vaccines against circulating and new emerging variants which may have
specific mutations that may enhance the virulent properties of the viral.
4.6.5. Potential Role of Senescence and Aging in Curtailing the COVID-19 Pandemic
Overall, the take home message is that the combination of neutralizing antibody
titres due to both age and VOC/VOI, must be considered when developing and designing
strategies for booster vaccinations and the duration of protection that would be conferred
by such additional booster doses and the clinical impact this would have on severe COVID-
19. It is also important to consider that this is fundamental in high-risk populations, such
as the elderly, who also have high levels of senescence cells. Further studies are also
needed to address the transcriptional, epigenetic, and functional reprogramming, termed
“trained immunity”, which occurs and drives immunological memory in those who have
recovered from COVID-19 [268–270]. One may query, is it plausible that these high levels of
senescence cells may play a key role in the immune response through involvement in some
of this transcriptional, epigenetic, and functional reprogramming, is waning immunity
and protection seen in the elderly especially due to senescence and is senescence partially
responsible for diminishing the immunological memory of T and B cells. If senescence is
involved, it could be an option for senolytics to be considered as a potential therapeutic
intervention.
5. Conclusions and Future Perspectives of Senescence as a Promising Biomarker and
Target in COVID-19
The effects ofSARS-CoV-2 infection and resultant severe COVID-19 symptomology is
likely driven by the highly destructive pathological hyperinflammatory response which
results in a derailed cytokine storm, thrombosis, vascular leakage, organ damage and
aberrant antibody immune responses, ultimately leading to high morbidity and mortality in
the most vulnerable. Our review highlights that senescence and aging together, potentially
play a central role in COVID-19 pathogenesis.
As alluded to already, therapeutic invention via senolytics is paving the way forward
in the field of aging research. Indeed, we draw upon the potential of utilizing senolytics
as viable therapeutic interventions or targets in COVID-19 to prevent severe infection in
patients and specifically aged patients. Strong evidence has been reported recently in old
mice where senescent cells became hyperinflammatory upon exposure to the SARS-CoV-2
virus. This resulted in enhanced SASP production of pre-existing senescent cells, increased
senescence, inflammation, and high mortality rates in these aged mice. Furthermore, this
study went on to show that the pharmacological removal of senescent cells via senolytic
(Fisetin or Dasatinib + Quercetin) treatment, in these aged mice, was shown to significantly
reduce senescence, inflammatory markers and mortality associated with COVID-19 [271].
These findings demonstrate the hypothetical rationale behind the therapeutic potential
of senolytics, particularly in aged patients who have a higher burden of senescence, to
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interrupt the initial triggered immune cascade, cytokine storm and hyperinflammation
evident in severe cases of SARS-CoV-2 infection. Indeed, Quercetin and Fisetin, which have
excellent safety profiles thus serve as attractive candidates, are currently being investigated
in COVID-19 trials as potential senolytic compounds for early intervention [272–274]. More-
over, it will be intriguing to explore if such strategies of early senolytic intervention could
help alleviate the chronic post-COVID-19 syndrome, Long COVID [275]. Interestingly,
findings from a recent study have shown that SARS-CoV-2 viral infection and subsequent
virus induced senescence (VIS) is a pathogenic driver of dysregulated cytokine storm and
tissue damage. This study found that patients infected with SARS-CoV-2 had markers of
senescence present in their airway mucosa and also had increased levels of SASP factors
within their serum. Excitingly, they showed that treatment with senolytics eradicated VIS
cells, alleviated COVID-19 lung disease and reduced inflammation in two COVID-19 driven
animal models [276]. This study highlights the potential clinical promise of senolytics as a
novel treatment against COVID-19, of which could also be translated to treating other viral
infections and ultimately enhance healthspan. This study along with a recently published
review [277], affirms our hypothesis that the senescence-aging-COVID-19 axis along with
the aging immune system has a paramount role in COVID-19 and a full understanding of
the mechanistic networks underpinning this axis will be vital in the future.
The COVID-19 pandemic has identified gaps in our current knowledge of the aged
immune system and the integral involvement of specific immune cell subsets. Even though
aging is considered to be one of the highest risk factors for COVID-19, the biological
mechanisms behind this are not fully known. Indeed, the role of senescence and immunose-
nescence in COVID-19 is not fully known either. Despite the large numbers of scientific
articles and preprints which are being published almost daily, the exact mechanisms behind
this conceptual axis of senescence-aging-COVID-19, the phenomena of immunosenescence,
novel sendotypes (senescent endotypes specifically) and immune regulation are not fully
known. Understanding the biological pathways involved in this disease will ultimately
lead to the identification of key genes and pathways which are linked to senescence-aging-
COVID-19, thus paving the way to developing novel drug targets and biomarkers for this
disease. Indeed, a recent study which combined gene co-expression network analysis with
artificial intelligence approaches has identified a potential novel gene signature which may
have clinical value in the pathogenesis of COVID-19 [278].
Therefore, extensive studies are required to further elucidate the mechanisms as to
why some patients develop more severe COVID-19 compared to others and to identify the
specific aspects of the aged immune system such as novel sendotypes (senescent endotypes)
which predispose the elderly to more severe clinical outcomes including mortality. It will
also be interesting to explore whether senescence is a confounding factor in waning immune
responses especially in the elderly and whether intervention via senolytics could mitigate
decreases evident in immune responses after vaccination. It would also be interesting to
explore if senescence is a factor involved in predisposing patients to Long COVID. Finally,
as many people worldwide have been infected with SARS-CoV-2 and as the pandemic is
very much still in its infancy and the long-term impacts from COVID-19 are yet to be fully
understood and it is likely that COVID-19 may instigate a long-lasting genomic imprint in
humans and their associated physiological processes.
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